Kyle Rezac, DO
Family Medicine · Fernandina Beach, FLNPI 1124448071
Payments from drug & device makers
Across 96 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$279
- AstraZeneca$230
- GSK$201
- Novo Nordisk$175
- Abbott$126
- Pfizer$80
- plus $494 from 18 others
What the payments were for
- Food & beverage$1,580100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $279 |
| AstraZeneca | 15 | $230 |
| GSK | 12 | $201 |
| Novo Nordisk | 11 | $175 |
| Abbott | 6 | $126 |
| Pfizer | 5 | $80 |
| AbbVie | 4 | $67 |
| Merck | 3 | $45 |
| Boehringer Ingelheim | 2 | $41 |
| Johnson & Johnson | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $38 |
| Nalpropion Pharmaceuticals LLC | 2 | $33 |
| Amgen | 2 | $32 |
| Exact Sciences | 2 | $30 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Concordia Pharmaceuticals Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,586 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $152,770 |
| EliquisApixaban | 45 | $69,439 |
| JardianceEmpagliflozin | 46 | $67,391 |
| FarxigaDapagliflozin Propanediol | 29 | $38,730 |
| XareltoRivaroxaban | 19 | $28,831 |
| JanuviaSitagliptin Phosphate | 20 | $27,210 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $25,202 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $22,062 |
| MounjaroTirzepatide | 20 | $21,904 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $18,012 |
| TrulicityDulaglutide | 16 | $14,488 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $13,007 |
| Testosterone | 39 | $12,918 |
| LinzessLinaclotide | 14 | $10,809 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $9,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $175 | $152,770119 claims |
| PfizerEliquis, Lyrica | $80 | $76,13156 claims |
| Boehringer IngelheimJardiance | $41 | $67,39146 claims |
| AstraZenecaFarxiga, Symbicort | $230 | $48,52149 claims |
| Lilly USA, LLCMounjaro, Trulicity | $279 | $36,39336 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $201 | $35,07047 claims |
| Johnson & JohnsonXarelto | $39 | $28,83119 claims |
| MerckJanuvia | $45 | $27,21020 claims |
| AbbVieLinzess, Synthroid | $67 | $14,51146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Fernandina Beach
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.